Enalare Therapeutics Inc. is focused on developing innovative therapies to address life-threatening acute respiratory and critical care conditions, particularly acute respiratory depression. Their lead drug candidate, ENA-001, is a novel chemical entity that is currently undergoing clinical trials. This compound is designed to provide a new mechanism of action that has shown both safety and efficacy, potentially transforming the treatment landscape for conditions such as drug overdose, post-operative respiratory depression, and apnea of prematurity. The company emphasizes the urgent need for effective therapeutic breathing stimulants, given the significant impact of respiratory depression on patient health and the healthcare system.

The development of ENA-001 aims to equip healthcare providers, including physicians and emergency responders, with new treatment options to manage respiratory depression across various clinical settings. Enalare Therapeutics is backed by a highly experienced team with a strong track record in the biopharmaceutical industry, dedicated to advancing their mission of improving patient outcomes in critical care scenarios. The company is actively seeking partnerships and licensing opportunities to further enhance the reach and impact of their innovative therapies.

United States

Enalare Therapeutics Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, including respiratory depression caused by drug overdose, post-surgery, and other conditions. The Company is planning to initiate pivotal studies for its lead compound ENA-001 in the near term.

Enalare Therapeutics Inc.

Company Details